ArticleCommunications medicine2024

First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.

Devalingam Mahalingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.